Nuveen
CLYM

Nuveen’s Climb Bio CLYM Stock Holding History

Nuveen’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
+85,935
New +$888K ﹤0.01% 2882
2025
Q2 		– Sell
-39,034
Closed -$47.6K – 3445
2025
Q1 		$47.6K Hold
39,034
– – ﹤0.01% 3261
2024
Q4 		$70.3K Hold
39,034
– – ﹤0.01% 3305
2024
Q3 		$199K Buy
+39,034
New +$276K ﹤0.01% 3222

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's CLYM Position: Q2 2026 in Review

Nuveen opened a new position in Climb Bio (CLYM) in Q2 2026: 85,935 shares worth $1.12M. The stake represents ﹤0.01% of the portfolio and ranks #2882 among its holdings. This is a return to the name: Nuveen previously reported a position in CLYM as recently as Q1 2025.

Nuveen first reported a position in CLYM in Q3 2024 and has held it in 4 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Nuveen held 85,935 shares of Climb Bio worth $1.12M as of Q2 2026.
  • Climb Bio was a new Nuveen position in Q2 2026.
  • Climb Bio made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2882 holding.
  • Nuveen first reported a position in Climb Bio in Q3 2024 and has held it in 4 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.